Albuterol Transition To CFC-Free: Increased Cost Could Affect Patient Access
Executive Summary
Increases in cost of albuterol inhalers due to the transition from chlorofluorocarbons to non-ozone depleting substances could affect patient access, members of FDA's Pulmonary-Allergy Drugs Advisory Committee suggested
You may also be interested in...
GSK Offers Price Freeze On Ventolin HFA In Bid For Early Phase-Out Of CFCs
GlaxoSmithKline has offered to freeze the wholesale price of its Ventolin HFA inhaler as part of its case for FDA to phase out chlorofluorocarbon albuterol metered-dose inhalers by December 31, 2005
GSK Offers Price Freeze On Ventolin HFA In Bid For Early Phase-Out Of CFCs
GlaxoSmithKline has offered to freeze the wholesale price of its Ventolin HFA inhaler as part of its case for FDA to phase out chlorofluorocarbon albuterol metered-dose inhalers by December 31, 2005
Ivax breath-activated HFA albuterol “approvable”
Ivax' breath-activated hydrofluoroalkane-propelled albuterol gets "approvable" letter from FDA, the company announces July 7. Ivax markets the breath-activated device as Easi-Breathe in Europe. Members of FDA's Pulmonary-Allergy Drugs Advisory Committee suggested delaying a chlorofluorocarbon ban to allow time for Ivax' and Sepracor's Xopenex HFA (levalbuterol) products to reach market (1"The Pink Sheet" June 21, 2004, p. 42)...